Key Highlights
- Aridis Pharmaceuticals focused on monoclonal antibodies for difficult hospital-treated infections, led by AR-301, targeting Staphylococcus aureus pneumonia.
- The company pursued a Qualified Infectious Disease Product designation for its lead program to support antibacterial development.
- Aridis's most recent SEC filings date to late 2023, and the stock has since moved off Nasdaq to over-the-counter trading.
- The last closing session showed no daily change and a Market Value of only a few thousand dollars.
Aridis Pharmaceuticals (OTC:ARDS) was once a Nasdaq-listed developer of antibody therapies for serious infectious diseases, but the stock now trades for a fraction of a cent on the over-the-counter market in the last closing session. The company's public disclosure has thinned dramatically, and its shares reflect deep distress rather than clinical momentum.
Company and Latest Development
Based in California, Aridis Pharmaceuticals focused on monoclonal antibodies and anti-infective therapeutics aimed at difficult hospital-treated infections, with a pipeline led by AR-301, an antibody candidate targeting Staphylococcus aureus pneumonia. The company pursued regulatory designations for its lead program, including a Qualified Infectious Disease Product designation intended to support development of novel antibacterials.
However, Aridis's most recent SEC filings date to late 2023, and the stock has since moved off Nasdaq to over-the-counter trading. No verified current clinical, regulatory or financing update is available from primary sources.
What Is Driving Attention Around ARDS?
The company has gone quiet. No single confirmed public catalyst explains the stock's current level; rather, the sub-penny price reflects a prolonged decline, a move off a national exchange and sparse reporting. The last closing session showed no daily change and a market value of only a few thousand dollars.
Attention to ARDS stems from its status as a distressed former biotech, not from any verified new trial result, approval or Partnership that can be documented.
Key Numbers and Company Position
Verifiable current financials for Aridis are limited given the lapse in regular reporting. What can be said with confidence is qualitative: the stock trades at a tiny fraction of a cent, its implied market Capitalization is negligible, and it now sits on the over-the-counter market rather than Nasdaq.
Historically a clinical-stage company, Aridis operated with recurring losses and dependence on external financing, a common profile for anti-infective developers without approved, revenue-generating products.
What Could Come Next?
For a distressed clinical-stage name, the potential catalysts would include any resumption of regular SEC disclosure, updates on the AR-301 program or other pipeline assets, new financing or partnership arrangements, or corporate actions such as a merger, asset sale or restructuring.
None of these is confirmed or scheduled. Given the funding-intensive nature of antibody development and the company's distressed posture, capital availability would be central to any revival.
Risks to Watch
The risks are substantial. As a sub-penny OTC stock, ARDS carries extreme illiquidity, wide spreads and the potential for total loss. Clinical-stage anti-infective development is inherently high-risk, with trial failure, regulatory setbacks and heavy cash needs all in play.
The lapse in current disclosure compounds the difficulty of due diligence, and further dilution, reverse splits or delisting-related actions cannot be ruled out.
From Designated Program to Information Vacuum
Aridis Pharmaceuticals illustrates how quickly a clinical-stage biotech's fortunes can fade, from a Nasdaq-listed anti-infective developer with designated programs to a quiet, sub-penny OTC name with limited disclosure.
The relevant items to monitor are basic: any return to regular SEC reporting, verifiable pipeline or AR-301 updates, and evidence of financing or strategic action. Until those materialize, ARDS remains a distressed, information-scarce situation rather than a company with a clear near-term catalyst.






Please wait processing your request...